Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 5/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24005916 | 0.80 | ULK1 (0.43) | ULK1ADORA1IRAK4HPGDSADORA3 | |
| SCHEMBL25625104 | 0.80 | ULK1 (0.45) | ULK1IRAK4SYKPAK4 | |
| SCHEMBL25626046 | 0.77 | JAK1 (0.40) | ULK1JAK2 | |
| SCHEMBL25625189 | 0.77 | GSK3A (0.46) | — | |
| SCHEMBL25613031 | 0.76 | JAK2 (0.36) | ULK1JAK2 | |
| SCHEMBL25613029 | 0.74 | FEN1 (0.39) | ULK1ADORA1IRAK4ADORA2ASYK | |
| SCHEMBL25626044 | 0.73 | NR3C1 (0.43) | ULK1JAK2 | |
| SCHEMBL25625108 | 0.73 | PIK3C3 (0.43) | ULK1IRAK4KITSYKPAK4 | |
| SCHEMBL13604904 | 0.73 | CDK8 (0.39) | ULK1IRAK4SYKPAK4 | |
| SCHEMBL25613025 | 0.71 | FEN1 (0.37) | ULK1ADORA1IRAK4ADORA2ASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | ULK1 1303/4885ADORA1 4836/4885IRAK4 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.